What is Zyprexa (olanzapine)?

What is Zyprexa (Olanzapine)?

Zyprexa (olanzapine) is an atypical antipsychotic medication that belongs to the thienobenzodiazepine class, FDA-approved for treating schizophrenia, acute mania in bipolar I disorder, and maintenance therapy in bipolar disorder. 1

Mechanism of Action

Olanzapine works through combined dopamine D2 and serotonin 5-HT2A receptor antagonism, though its exact mechanism remains incompletely understood 1. The drug binds with high affinity to multiple receptor systems including:

• Serotonin receptors (5-HT2A, 5-HT2C, 5-HT6)
• Dopamine receptors (D1-4)
• Histamine H1 receptors
• Alpha-1 adrenergic receptors
• Muscarinic M1-5 receptors (moderate affinity)

This multi-receptor profile explains both its therapeutic effects and side effect profile 1.

FDA-Approved Indications

For adults, olanzapine is approved for:

• Acute mania in bipolar I disorder 2
• Maintenance therapy in bipolar disorder 2
• Schizophrenia (acute and maintenance treatment) 3
• Bipolar depression when combined with fluoxetine 2

For adolescents, olanzapine has more limited approval, though it is used off-label in clinical practice for early-onset schizophrenia and bipolar disorder 2, 3.

Available Formulations

Zyprexa comes in three forms 1:

1. Oral tablets: 2.5,7.5,10,15, and 20 mg
2. Orally disintegrating tablets (ZYDIS): 5,10,15, and 20 mg (dissolves in mouth within seconds)
3. Intramuscular injection: 10 mg vials for acute agitation

Pharmacokinetics

• Peak plasma levels: 5-8 hours after oral dosing 4, 5
• Half-life: Approximately 31 hours (range 21-54 hours) 4
• Dosing frequency: Once daily due to long half-life
• Food effect: None—can be taken with or without food

Clinical Efficacy

Olanzapine demonstrates robust efficacy across multiple psychiatric conditions:

• Superior to haloperidol for negative symptoms and depression in schizophrenia 6
• Comparable to haloperidol for positive psychotic symptoms 6
• Effective for acute agitation when given intramuscularly, with onset within 2 hours 7
• Lower relapse risk compared to haloperidol in 1-year studies 6

In head-to-head comparisons with risperidone, results are mixed—one 28-week study showed olanzapine superior for negative and depressive symptoms 6, while an 8-week study suggested risperidone may be superior for positive symptoms 6.

Dosing

Standard starting dose: 5-10 mg once daily 1

• Typical range: 5-20 mg/day
• Maximum FDA-approved dose: 20 mg/day
• Higher doses (≥40 mg/day) have been used off-label for treatment-resistant cases but carry increased risk of adverse effects 8

For acute agitation (IM): 10 mg intramuscularly, may repeat 7

Critical Adverse Effects

Most Common Side Effects

The most significant concerns with olanzapine are metabolic side effects, particularly:

• Weight gain: Occurs in ~40% of patients, especially with higher starting doses 5, 9
• Metabolic syndrome: Increased risk of dyslipidemia, hyperglycemia, and Type 2 diabetes 10
• Somnolence and sedation 11, 5
• Constipation (dose-dependent, more common at doses ≥40 mg/day) 8
• Dry mouth (anticholinergic effect) 11

Advantages Over Typical Antipsychotics

• Significantly fewer extrapyramidal symptoms compared to haloperidol 6, 3
• No risk of agranulocytosis (unlike clozapine) 11
• No clinically significant QTc prolongation (unlike some other antipsychotics) 9
• Lower risk of tardive dyskinesia 2
• No significant hyperprolactinemia (unlike risperidone) 6

Serious but Rare Risks

• Neuroleptic malignant syndrome (rare) 1
• Seizures (especially in overdose) 1
• Hepatic transaminase elevations (usually transient and asymptomatic) 11, 6

Special Populations

Adolescents

Metabolic side effects are MORE pronounced in youth compared to adults 12. Olanzapine should be considered second-line in adolescents due to substantial metabolic liability, with preference for agents with better metabolic profiles 12. When used, requires stringent metabolic monitoring 12.

Elderly/Dementia

Olanzapine has been studied for agitation in dementia at lower doses (2.5-5 mg) 7, though all antipsychotics carry black box warnings for increased mortality in elderly patients with dementia-related psychosis.

Monitoring Requirements

Given the metabolic risks, patients on olanzapine require:

• Baseline and periodic monitoring of:
  • Weight and BMI
  • Fasting glucose and HbA1c
  • Lipid panel
  • Blood pressure

Metformin co-administration may help prevent or mitigate olanzapine-induced weight gain in patients with schizophrenia 10.

Clinical Positioning

Olanzapine is positioned as a first-line atypical antipsychotic for adults with schizophrenia or bipolar disorder, particularly when:

• Negative symptoms are prominent
• Depressive symptoms coexist
• Extrapyramidal side effects are a concern with other agents
• Patient has failed typical antipsychotics

However, it should NOT be first-line when:

• Patient has pre-existing metabolic syndrome, diabetes, or significant obesity
• Patient is an adolescent (use second-line due to metabolic risks)
• Weight gain would be particularly problematic for adherence

Overdose Management

In overdose, supportive care is the mainstay as there is no specific antidote 1. Key points:

• Activated charcoal (1 g) reduces absorption by ~60% if given early 1
• Do NOT use epinephrine for hypotension (may worsen due to alpha-blockade); use other vasopressors 1
• Monitor for sedation, extrapyramidal symptoms, seizures, and cardiac arrhythmias 1
• Fatalities have been reported with doses as low as 450 mg, though survival has occurred with ~2 g 1

Cost Considerations

While olanzapine has higher acquisition costs than typical antipsychotics like haloperidol, pharmacoeconomic analyses show it may reduce overall treatment costs through decreased hospitalizations and improved outcomes 6.